Cargando…

Favipiravir: Acute pancreatitis following an off-label use: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954673/ http://dx.doi.org/10.1007/s40278-021-92381-5

Ejemplares similares

Favipiravir: Acute psychosis following off-label use: case report
Publicado: (2022)

Favipiravir: Hyperuricaemia and acute gouty arthritis following off-label use: case report
Publicado: (2020)

Favipiravir: Liver injury following an off-label use: case report
Publicado: (2021)

Favipiravir: Lack of efficacy following off-label treatment: case report
Publicado: (2021)

Favipiravir/hydroxychloroquine/methylprednisolone: Nephrotoxicity following an off-label use: 2 case reports
Publicado: (2021)

Azithromycin/favipiravir: Sinus bradycardia following interaction and off label use: case report
Publicado: (2022)

Favipiravir: Hyperuricaemia and lack of efficacy following off-label use: 2 case reports
Publicado: (2022)

Favipiravir/voriconazole: Hyperuricaemia, transaminitis and off-label use: case report
Publicado: (2021)

Azithromycin/favipiravir/hydroxychloroquine: Hypoglycaemia and off label use: case report
Publicado: (2021)

Antineoplastics/ciclesonide/favipiravir: Pancytopenia and off-label use: case report
Publicado: (2022)

Favipiravir/methylprednisolone: Off-label use and lack of efficacy: case report
Publicado: (2022)

Favipiravir/meropenem/vancomycin: Cholestatic liver injury following off-label use: case report
Publicado: (2021)

Favipiravir/hydroxychloroquine/oseltamivir: Tonic clonic seizures following off label use: case report
Publicado: (2020)

Enoxaparin-sodium/favipiravir: Acute generalised exanthematous pustulosis and off-label use: case report
Publicado: (2022)

Favipiravir: Bilateral foot ulcers, vasculitis and off-label use : case report
Publicado: (2021)

Colchicine/favipiravir/prednisolone: Lack of efficacy and off label use: case report
Publicado: (2021)

Azithromycin/favipiravir/hydroxychloroquine: Lack of efficacy and off-label use: case report
Publicado: (2021)

Favipiravir/levofloxacin/paracetamol: Severe thrombocytopenia and off-label use: case report
Publicado: (2021)

Ceftriaxone/favipiravir/vancomycin: Lack of efficacy and off-label use: case report
Publicado: (2022)

Favipiravir/tocilizumab: Increased lymphocyte count and transaminases following off-label use: 4 case reports
Publicado: (2021)

Azithromycin/favipiravir/hydroxychloroquine: Ventricular tachycardia and off-label use: 2 case reports
Publicado: (2020)

Favipiravir: Fever and elevated uric acid level following off-label therapy: 2 case reports
Publicado: (2021)

Favipiravir: Lack of efficacy secondary to off label use in COVID-19: Case report: case report
Publicado: (2021)

Ciclesonide/favipiravir/lopinavir/ritonavir: Off-label use, pancytopenia and liver dysfunction: case report
Publicado: (2021)

Favipiravir: Maculopapular rash, urticarial rash and Stevens–Johnson syndrome following off label use: 5 case reports
Publicado: (2022)

Dexamethasone/favipiravir: Rebound effect leading to pulmonary embolism and deep vein thrombosis following off-label use: case report
Publicado: (2022)

Aspirin/favipiravir: Haemolytic anaemia, decrease in his lymphocyte count and off-label use: case report
Publicado: (2021)

Dexamethasone/favipiravir/methylprednisolone: Hyperglycaemia, masking of cytokine storm and off-label use: 2 case reports
Publicado: (2021)

Dexamethasone/favipiravir/antibacterials: Cytomegalovirus pneumonia, Candida parapsilosis infection and off label use: case report
Publicado: (2021)

Dexamethasone/favipiravir/metoclopramide: Sinus bradycardia, deranged liver enzymes and off-label use: case report
Publicado: (2021)

Chloroquine/favipiravir/rituximab: COVID-19-pneumonia, off-label use and lack of efficacy: case report
Publicado: (2022)

Baricitinib/propofol: Pancreatitis following off-label use: case report
Publicado: (2022)

Multiple drugs: Acute pancreatitis and off label use: case report
Publicado: (2021)

Azithromycin/favipiravir/hydroxychloroquine interactions: Corrected QT (QTc) interval prolongation due to pharmacodynamic interaction following off label use: 2 case reports
Publicado: (2021)

Convalescent-anti-sars-cov-2-plasma/dexamethasone/favipiravir: Avascular necrosis of femoral head and off-label use: case report
Publicado: (2021)

Dexamethasone: Acute pulmonary histoplasmosis following Off-label use: case report
Publicado: (2021)

Hydroxychloroquine: Acute haemolytic anaemia following off-label use: case report
Publicado: (2020)

Ivermectin: Acute hepatocellular injury following off-label use: case report
Publicado: (2022)

Favipiravir: Acute generalised exanthematous pustulosis: case report
Publicado: (2021)

Hydroxychloroquine: Acute generalised exanthematous pustulosis following off-label use: case report
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4ms5kob8pv0tcf57ldih3tijsf